LYTGOBI can provide
The power you want.
The care patients need.
- 42% ORRa (95% CI: 32%, 52%)1
- 9.7 months mDoR (95% CI: 7.6, 17.1) (N=103)1
Take on advanced cholangiocarcinoma (CCA) with LYTGOBI, an approved irreversibly binding FGFR inhibitor designed to help you target appropriate patients and offer personalized support along their treatment journey.1-3
aResponses were partial in the single-arm, phase 2 FOENIX-CCA2 study
Taiho Oncology Patient Support™ offers personalized services to help patients, caregivers, and healthcare professionals access Taiho Oncology products.
- Insurance Coverage Support
- Patient Affordability Assistance
- Personalized Nurse Support
For updates about LYTGOBI,
CI=confidence interval; FGFR=fibroblast growth factor receptor; mDOR=median duration of response; ORR=overall response rate.
LYTGOBI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022.2.
Kalyukina M, Yosaatmadja Y, Middleditch M, Patterson A, Smaill J, Squire C. TAS-120 cancer target binding: Defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem. 2019;14(4):494-500.3.
Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80(22):4986-4997.